Holen Sie sich die Stockscreener-App
3.99
6.68%
0.2499
Vorhandelsmarkt:
4.91
0.92
+23.06%
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
ERNAW Ernexa to share quarterly earnings context and updated clinical pipeline progress with investors this month.Investment Community Signals - Newser
Eterna Therapeutics Implements 1-for-25 Reverse Stock Split - TipRanks
Ernexa Therapeutics announces 1-for-25 reverse stock split; shares down - MSN
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split - marketscreener.com
ERNAW (Ernexa Therapeutics) Shiller PE Ratio : (As of Apr. 27, 2026) - GuruFocus
ERNAW (Ernexa Therapeutics) Cyclically Adjusted PS Ratio : (As of Apr. 22, 2026) - GuruFocus
Is Ernexa Therapeutics (ERNA) stock showing breakout potential (Loses Ground) 2026-04-20Intraday Trading - Newser
ERNAW | Ernexa Therapeutics Inc. Warrants Insider Trading - Quiver Quantitative
Is Ernexa (ERNAW) Stock Ready to Move | Price at $0.04, Down 29.86%Trader Community Insights - Newser
ERNA Should I Buy - Intellectia AI
Is Ernexa Therapeutics Inc in a long term uptrend2026 Market Outlook & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Institution Moves: Can Ernexa Therapeutics Inc continue delivering strong returns2026 Short Interest & Low Drawdown Trading Techniques - baoquankhu1.vn
Analyst Calls: Is Ernexa Therapeutics Inc stock a good pick for beginners2026 Levels & Fast Moving Trade Plans - baoquankhu1.vn
Signal Recap: Will Ernexa Therapeutics Inc outperform tech stocksPrice Action & AI Driven Stock Reports - baoquankhu1.vn
Is Ernexa (ERNAW) Stock Slowing Down | Price at $0.06, Up 96.67%Volume Breakout - Newser
Chart Watch: Will Ernexa Therapeutics Inc outperform tech stocks2026 Top Gainers & Precise Buy Zone Identification - baoquankhu1.vn
ERNA PE Ratio & Valuation, Is ERNA Overvalued - Intellectia AI
Is Ernexa Therapeutics (ERNA) Stock Overvalued Now | Price at $0.20, Down 4.76%Long Term Investing - Newser
Ernexa Therapeutics (NASDAQ: ERNA) OKs Board-authorized 1-for-10–1-for-25 reverse split - Stock Titan
ERNAW Technical Analysis | Trend, Signals & Chart Patterns | ERNEXA THERAPEUTICS INC31 (NASDAQ:ERNAW) - ChartMill
ERNEXA THERAPEUTICS INC31 (ERNAW) Stock Chart - ChartMill
Ernexa plans ovarian cancer trial for cell therapy ERNA-101 By Investing.com - Investing.com Canada
Deep tumor regressions put Ernexa on track for 2026 human trial - Stock Titan
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 - GlobeNewswire
[EFFECT] Ernexa Therapeutics Inc. SEC Filing - Stock Titan
Momentum Shift: Is Ernexa Therapeutics Inc a strong candidate for buy and holdLayoff News & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Eterna Therapeutics Faces Nasdaq Delisting Risk After Notice - The Globe and Mail
Ernexa Therapeutics Inc. Files Form 8-K: Notice of Nasdaq Delisting and Company Response – March 2026 - Minichart
Ernexa Therapeutics receives Nasdaq delisting notice due to minimum bid price By Investing.com - Investing.com India
Ernexa Therapeutics receives Nasdaq delisting notice due to minimum bid price - Investing.com Australia
Ernexa Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Resistance Check: Is PAVmed Inc stock a value trap2026 Key Lessons & Precise Buy Zone Tips - baoquankhu1.vn
AI Stocks: Why is Ernexa Therapeutics Inc stock going upTrade Risk Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
Ernexa Therapeutics Inc may offer up to $50 million of securitiesSEC filing - marketscreener.com
Ernexa Therapeutics IncMay Offer Up To $50 Million Of SecuritiesSEC Filing - TradingView
Ernexa Therapeutics Inc. 2025 Annual Report: Synthetic Allogeneic iMSC Therapy, Business Overview, Key Risks, and Patent Portfolio - Minichart
Ernexa Therapeutics 2025 10-K: $0.0M Revenue, Net Loss $(14.08)M - TradingView
Ernexa Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. - marketscreener.com
Aug Wrap: Is Ernexa Therapeutics Inc exposed to currency risksPortfolio Growth Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Ernexa Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Sentiment: What is Ernexa Therapeutics Incs book value per shareJuly 2025 Price Swings & Accurate Entry/Exit Alerts - baoquankhu1.vn
Breakout Move: Is Ernexa Therapeutics Inc a strong candidate for buy and holdJuly 2025 Institutional & Pattern Based Trade Signal System - baoquankhu1.vn
Ernexa Therapeutics Inc.Common Stock (NQ: ERNA - FinancialContent
Comparing Aditxt (NASDAQ:ADTX) & Ernexa Therapeutics (NASDAQ:ERNA) - Defense World
ERNA Technical Analysis & Stock Price Forecast - Intellectia AI
Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosure - The Globe and Mail
Ernexa Therapeutics updates investor presentation, posts Exhibit 99.1 on website - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) furnishes new February 2026 investor presentation - Stock Titan
Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 11.4% – Time to Sell? - Defense World
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - GlobeNewswire
Will Ernexa Therapeutics Inc. stock outperform value stocksQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Insider Stock Purchases: February 18, 2026 - Quiver Quantitative
Ernexa therapeutics ten percent owner Cherington buys $2m in stock By Investing.com - Investing.com India
Ernexa therapeutics ten percent owner Cherington buys $2m in stock - Investing.com
ERNA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will Ernexa Therapeutics Inc. outperform tech stocksJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):